SUPN Q1 2019 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q1 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$85M-5.5% YoY

Gross Profit

$82M95.7% margin

Operating Income

$25M29.7% margin

Net Income

$18M21.5% margin

EPS (Diluted)

$0.34

QoQ Revenue Growth

-26.3%

Cash Flow

Operating Cash Flow

$33M

Free Cash Flow

$33M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$545M

Stockholders' Equity

$480M

Cash & Equivalents

$123M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$85M	$90M	-5.5%
Gross Profit	$82M	$87M	-6.2%
Operating Income	$25M	$31M	-19.0%
Net Income	$18M	$26M	-30.4%

Revenue Segments

Product

$83M49%

Trokendi X R

$64M38%

Oxtellar X R

$19M12%

Royalty

$2M1%